Regulatory shifts and accelerated pathways for rare diseases, gene therapies, and bespoke treatments

FDA Policy for Rare and Gene Therapies

Recent years have seen transformative shifts in regulatory approaches aimed at accelerating the development and approval of therapies for rare diseases, gene therapies, and highly individualized treatments. The U.S. Food and Drug Administration (FDA) has been at the forefront of this evolution, introducing adaptive frameworks and streamlined pathways that balance rapid access with robust safety and efficacy oversight. These regulatory innovations are critical in unlocking the potential of bespoke gene editing technologies and rare disease therapeutics, which often face unique developmental challenges.

New FDA Standards Around Trial Requirements and Individualized Therapies

A pivotal regulatory shift involves the FDA's move to relax traditional clinical trial requirements for certain drug approvals. Historically, the agency required two adequate and well-controlled studies to grant approval. However, emerging guidance signals a transition toward accepting a single, well-designed trial as sufficient for approval in many contexts, especially for therapies addressing urgent unmet needs or rare conditions.

In a recent commentary published in the New England Journal of Medicine, FDA Commissioner Dr. Robert Califf emphasized this evolution toward a one-trial default, highlighting the potential to reduce development timelines without compromising scientific rigor.
This shift is particularly impactful for rare disease therapies and gene editing approaches, where patient populations are small, and conducting multiple large-scale trials is infeasible.

Complementing this, the FDA has launched an adaptive individualized therapy framework targeting ultra-rare diseases and bespoke gene therapies. This framework leverages near real-time data, including AI-enhanced post-market surveillance, to enable dynamic risk stratification and tailored treatment regimens. The approach reflects a broader trend toward personalized regulatory oversight, accommodating the heterogeneity of patient responses and the complexity of advanced biologics.

Orphan, Fast-Track, and Bespoke Frameworks Impacting Development Speed

To further accelerate therapeutic availability, the FDA continues to refine and expand special regulatory designations and programs tailored to rare and complex conditions:

The Orphan Drug Act incentives remain fundamental, providing market exclusivity and regulatory support for therapies targeting diseases affecting fewer than 200,000 patients in the U.S. The agency’s recent proposals aim to strengthen this framework by integrating better natural history data and genomic insights, which improve trial design and endpoint selection.
The Fast Track, Breakthrough Therapy, and Priority Review designations are increasingly utilized for gene therapies and antisense oligonucleotide drugs. For example, the Priority Review acceptance of olezarsen’s supplemental New Drug Application (NDA) for severe hypertriglyceridemia underscores FDA’s commitment to expediting novel genetic and metabolic treatments.
Importantly, a new bespoke gene therapy approval pathway has been illuminated by the FDA to address the unique challenges of individualized gene editing treatments. This pathway contemplates small-batch, patient-specific manufacturing and accelerated review processes, recognizing that traditional mass production and large trials are impractical for ultra-rare or one-off therapies.
On February 23, 2026, the FDA formally proposed a framework to speed rare disease gene therapy approvals, focusing on flexible clinical trial designs, surrogate endpoints, and enhanced real-world evidence integration. This proposal aims to harmonize regulatory expectations with the rapid innovation occurring in genetic medicine.

Integration of AI and Real-World Evidence in Regulatory Processes

A defining feature of the FDA’s new regulatory landscape is the integration of artificial intelligence (AI) and real-world data to enhance decision-making throughout the drug lifecycle:

AI-driven surveillance systems monitor post-market safety signals in near real-time, enabling dynamic adjustment of dosing, patient eligibility, and risk mitigation strategies for complex biologics and gene therapies.
These tools allow regulators to respond swiftly to emerging safety concerns and optimize therapeutic profiles, which is especially critical for individualized therapies where patient variability is high.
The adaptive regulatory frameworks also support accelerated approval pathways by incorporating biomarker-driven endpoints and surrogate markers validated through extensive real-world datasets.

Industry and Regulatory Perspectives

FDA Commissioner Dr. Robert Califf has articulated the agency’s vision:

“Our regulatory evolution, powered by AI and comprehensive real-world evidence, equips us to responsibly expedite patient access to transformative cardio-renal-metabolic therapies while vigilantly safeguarding safety and equity.”

This vision is echoed across the biomedical sector, where stakeholders acknowledge that regulatory agility is indispensable for translating cutting-edge scientific advances—like gene editing and bespoke nucleic acid therapies—into clinical realities.

Summary

The regulatory landscape in 2028 reflects a paradigm shift toward streamlined, flexible, and data-driven approval processes for rare diseases, gene therapies, and individualized treatments. Key developments include:

Dropping the two-study requirement in favor of a single pivotal trial under specific circumstances, reducing time and cost barriers.
Launching a specialized framework for ultra-rare and bespoke therapies, enabling tailored regulatory oversight and expediting patient access.
Continued use and refinement of orphan, fast-track, and priority review programs to accelerate development and incentivize innovation in rare disease and genetic medicine.
Integration of AI-enhanced post-market surveillance and real-world evidence to support adaptive regulatory decisions and ensure ongoing safety monitoring.

Together, these innovations position the FDA and the broader healthcare ecosystem to meet the unique challenges of next-generation therapies, ensuring that patients with rare and complex conditions benefit from timely, safe, and effective treatment options.

Sources (9)